Mumps Vaccine Market: Global Industry Analysis and Forecast (2022-2027) Trends

Mumps Vaccine Market was valued at US$ 584 Mn. in 2021. Global Mumps Vaccine Market size is expected to grow at a CAGR of 9.4 % through the forecast period.

Mumps Vaccine Market Overview:

Vaccines for measles, mumps, and rubella (MMR) are a mix of live viruses that are injected. The live viruses are rendered inactive and unable to multiply in human cells while the immune system fights and protects against the infection. The MMR vaccine is effective for a long time. The MMR vaccine causes fever, rash, cough, bodily pain, headache, nausea, and serious side effects such as infection of the ovaries and testicles, deafness, and death in rare cases. The MMR vaccine is given to babies between the ages of 12 and 15 months, and between the ages of 3 and 4 years for the second dose. The virus replicates in the respiratory system and transmits to others through aerosolized droplets in an enclosed environment. The most common symptom, fever, appears 10-12 days after the infection. Immunosuppressive medicine users, on the other hand, should avoid MMR vaccinations since the virus can spread and cause disease. Mumps Vaccine Market To know about the Research Methodology :- Request Free Sample Report 2021 is considered as a base year to forecast the market from 2022 to 2027. 2021’s market size is estimated on real numbers and outputs of the key players and major players across the globe. The past five years' trends are considered while forecasting the market through 2027. 2021 is a year of exception and analysis, especially with the impact of lockdown by region.

Mumps Vaccine Market Dynamics:

Market Driver: High Prevalence of Mumps in Mid and low-income Country: Mumps disease is quite common in low- and middle-income nations including India, China, Vietnam, and portions of Africa. Mumps affects the parotid glands, salivary glands below and in front of the ears. The disease spreads through infected saliva. The following metrics were used to identify Mumps disease: structural heart problems in 80% of the patients, Patients may suffer from Fever, Headache, loss of appetite, and Strong Pain while chewing. Around 650 suspected cases were investigated in five different locations across India, with close to 150 of them being confirmed as laboratory-confirmed Mumps Cases. Mortality occurred in 25% of the children under the age of two years, according to the data. By 2022, the market is expected to rise significantly due to increased investment by pharmaceutical companies in R&D efforts, as well as an increase in the number of hospitals and healthcare facilities. Moreover, rising funding and campaigning by non-government organizations are expected to increase Mumps Vaccine’s popularity, which will drive demand. Mumps vaccine market growth is expected to be boosted by macro indicators such as increased economic development and per capita income in developing economies such as China, India, and Brazil over the forecast period. Hence, the Prevalence of Mumps Disease and increased investment by pharmaceutical companies in mid and low-income Countries can increase the growth of the Mumps Vaccine Market during the forecast period. Immunization Program Initiated by WHO and Associated NGOs: Before the Mumps vaccine, 5 kids out of every 1000 were born with Mumps Disease. People who received at least one dose of the Mumps virus vaccine had a 97% effectiveness rate. The three WHO components from regions such as the United States, Europe, and the Western Pacific have aspired and established policies with Mumps elimination goals. RCV has been successfully implemented in 152 nations out of 194. Furthermore, according to WHO guidelines, implementing a high-quality surveillance system is a vital strategy for achieving Mumps elimination. Most nations in the Americas, Europe, and the Western Pacific Region now have surveillance programs for Mumps and Mumps during pregnancy. In developing countries like India NGOs are working with the government and conducting a lot of vaccination programs for children and adults. Hence, these factors are also expected to increase the growth of the Mumps Vaccine Market. Market Restraints: Stringent Regulation and lack of Accessibility: During the forecast period, increased regulatory procedures in production and distribution, as well as rising prices, are expected to hinder the market growth. Limited vaccination coverage, combined with exorbitant costs associated with vaccine shipping and storage, will limit the market progress during the forecast period. Furthermore, strict government requirements for product approval will delay the entry of new products into the market, limiting the mumps vaccine market growth. Furthermore, a shortage of raw materials is also expected to cause supply-demand mismatches, limiting the growth of the Mumps Vaccine Market. Mumps Vaccine is active for only 8 hours without a refrigerator. To increase the shelf life, it is needed to keep in the refrigerator which will increase the shipping and transportation cost. A vaccine is a biological substance when it comes in contact with the environment it gets contaminated and changes its properties. So, these are some factors that hinder the growth of the Mumps Vaccine Market during the forecast period.

Mumps Vaccine Market Segment Analysis:

Based on the Age Group, the Mumps Vaccine Market is segmented into Pediatric and Adult. Pediatric Segment holds the largest share in terms of volume. The potential size of these is because of the growing birth rate and increasing pediatric clinics. Before Mumps Vaccine, 5 kids out of every 1000 were born with Mumps Disease. People who received at least one dose of the Mumps virus vaccine had a 97 percent effectiveness rate. Furthermore, the adult segment is also expected to grow at a healthy CAGR during the forecast period. This is because of rising in Research & Development and a strong pipeline of Mumps Vaccine products. Hence, the high prevalence and effectiveness of the mumps virus are expected to increase the growth of the Pediatric and Adult segment in the Mumps Vaccine Market during the forecast period. mumps vaccine market Based on the End-Users, the Mumps Vaccine Market is segmented into Hospitals, NGOs, Paediatric Clinics, and Others. Pediatric clinics held the largest share in 2021. It's because the WHO advises that the first dose of MMR vaccination should be given between the ages of 12 and 15, and parents and guardians continue to favor pediatric clinics because of the low-hassle and uncomplicated immunization process. Adults born after 1957 are required to have the MMR vaccine, according to the most recent guidelines. Also, the elderly are particularly vulnerable to such virulent strains, and vaccinations can provide significant protection against symptomatic instances. However, NGOs are expected to increase at the greatest rate, with a CAGR of 5.1% during the forecast period. Because in many countries NGOs collaborate with the government and conduct a vaccination program for children and adults. It is expected that during the forecast period the demand for Mumps vaccine will increase. Hence, an increase in demand can boost the growth of the Mumps Vaccine Market.

Mumps Vaccine Market Regional Insights:

The North America region dominated the market with a 34 % share in 2021. The North America region is expected to witness significant growth at a CAGR of 11% through the forecast period. It is expected that during the forecast period North America region remains dominant in the Mumps Vaccine Market because of the high prevalence of the disease and increasing investment by the companies. In addition, the presence of key players in this region makes North America dominate the Mumps Vaccine Market. Also, Asia Pacific is also expected to grow more in Mumps Vaccine Market. Because of the high prevalence of disease and dense population. The objective of the report is to present a comprehensive analysis of the global Mumps Vaccine Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help understand the Mumps Vaccine Market dynamic and structure by analyzing the market segments and projecting the Mumps Vaccine Market size. Clear representation of competitive analysis of key players by Vehicle type, price, financial position, product portfolio, growth strategies, and regional presence in the Mumps Vaccine Market make the report investor’s guide.

Mumps Vaccine Market Scope: Inquire before buying

Global Mumps Vaccine Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2027
Historical Data: 2017 to 2021 Market Size in 2021: US $ 584 Mn.
Forecast Period 2022 to 2027 CAGR: 9.4% Market Size in 2027: US $ 1000 Mn.
Segments Covered: by Age Group • Pediatric • Adult
by Distribution Channels • Hospitals Pharmacies • Drug Stores • Retail Pharmacies
by Product Type • Monovalent • Combinational • Divalent • Trivalent • Others
by End-User • Pediatric Clinic • Hospitals • NGOs • Others

Mumps Vaccine Market by Region

• North America • Europe • The Asia Pacific • South America • The Middle East and Africa

Mumps Vaccine Market Key Players

• MedImmune • Johnson & Johnson • Merck & Co., Inc. • Sanofi • Serum Institute of India • Bavarian Nordic • Astellas Pharma India • CSL Limited • Emergent BioSolutions • GlaxoSmithKline • Panacea Biotec, Ltd. • Biological E Limited • Bharat Biotech Ltd. • Novavax, Inc. • Novartis • Sinovac Biotech, Ltd. • Incepta Vaccine Limited • Valneva SE • VBI Vaccines • PT Bio Farma Frequently Asked Questions: 1] What segments are covered in the Global Mumps Vaccine Market report? Ans. The segments covered in the Mumps Vaccine Market report are based on Product Type, End-Users, Age Group, and Distribution Channel. 2] Which region is expected to hold the highest share in the Global Mumps Vaccine Market? Ans. The North America region is expected to hold the highest share in the Mumps Vaccine Market. 3] What is the market size of the Global Mumps Vaccine Market by 2027? Ans. The market size of the Mumps Vaccine Market by 2027 is expected to reach US$ 1000 Mn. 4] What is the forecast period for the Global Mumps Vaccine Market? Ans. The forecast period for the Mumps Vaccine Market is 2022-2027. 5] What was the market size of the Global Mumps Vaccine Market in 2021? Ans. The market size of the Mumps Vaccine Market in 2021 was valued at US$ 584 M
1. Global Mumps Vaccine Market Size: Research Methodology 2. Global Mumps Vaccine Market Size: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Mumps Vaccine Market Size 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Mumps Vaccine Market Size: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • The Asia Pacific • South America 3.12. COVID-19 Impact 4. Global Mumps Vaccine Market Size Segmentation 4.1. Global Mumps Vaccine Market Size, by Age Group (2021-2027) • Pediatric • Adult 4.2. Global Mumps Vaccine Market Size, by Distribution Channels (2021-2027) • Hospitals Pharmacies • Drug Stores • Retail Pharmacies 4.3. Global Mumps Vaccine Market Size, by Product Type (2021-2027) • Monovalent • Combinational • Divalent • Trivalent • Others 4.4. Global Mumps Vaccine Market Size, by End-Users (2021-2027) • Pediatric Clinic • Hospitals • NGOs • Others 5. North America Mumps Vaccine Market (2021-2027) 5.1. North America Mumps Vaccine Market Size, by Age Group (2021-2027) • Pediatric • Adult 5.2. North America Mumps Vaccine Market Size, by Distribution Channels (2021-2027) • Hospitals Pharmacies • Drug Stores • Retail Pharmacies 5.3. North America Mumps Vaccine Market Size, by Product Type (2021-2027) • Monovalent • Combinational • Divalent • Trivalent • Others 5.4. North America Mumps Vaccine Market Size, by End-Users (2021-2027) • Pediatric Clinic • Hospitals • NGOs • Others 5.5. North America Mumps Vaccine Market, by Country (2021-2027) • The United States • Canada • Mexico 6. European Mumps Vaccine Market (2021-2027) 6.1. European Mumps Vaccine Market, by Age Group (2021-2027) 6.2. European Mumps Vaccine Market, by Distribution Channels (2021-2027) 6.3. European Mumps Vaccine Market Size, by Product Type (2021-2027) 6.4. European Mumps Vaccine Market Size, by End-Users (2021-2027) 6.5. European Mumps Vaccine Market, by Country (2021-2027) • The UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Mumps Vaccine Market (2021-2027) 7.1. Asia Pacific Mumps Vaccine Market, by Age Group (2021-2027) 7.2. Asia Pacific Mumps Vaccine Market, by Distribution Channels (2021-2027) 7.3. Asia Pacific Mumps Vaccine Market Size, by Product Type (2021-2027) 7.4. Asia Pacific Mumps Vaccine Market Size, by End-Users (2021-2027) 7.5. Asia Pacific Mumps Vaccine Market, by Country (2021-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. The Middle East and Africa Mumps Vaccine Market (2021-2027) 8.1. The Middle East and Africa Mumps Vaccine Market, by Age Group (2021-2027) 8.2. The Middle East and Africa Mumps Vaccine Market, by Distribution Channels (2021-2027) 8.3. The Middle East and Africa Mumps Vaccine Market Size, by Product Type (2021-2027) 8.4. The Middle East and Africa Mumps Vaccine Market Size, by End-Users (2021-2027) 8.5. The Middle East and Africa Mumps Vaccine Market, by Country (2021-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Mumps Vaccine Market (2021-2027) 9.1. South America Mumps Vaccine Market, by Age Group (2021-2027) 9.2. South America Mumps Vaccine Market, by Distribution Channels (2021-2027) 9.3. South America Mumps Vaccine Market, by Product Type (2021-2027) 9.4. South America Mumps Vaccine Market, by End-Users (2021-2027) 9.5. South America Mumps Vaccine Market, by Country (2021-2027) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. MedImmune 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Johnson & Johnson 10.3. Merck & Co., Inc. 10.4. Sanofi 10.5. Serum Institute of India 10.6. Bavarian Nordic 10.7. Astellas Pharma India 10.8. CSL Limited 10.9. Emergent BioSolutions 10.10. GlaxoSmithKline 10.11. Panacea Biotec, Ltd. 10.12. Biological E Limited 10.13. Bharat Biotech Ltd. 10.14. Novavax, Inc. 10.15. Novartis 10.16. Sinovac Biotech, Ltd. 10.17. Incepta Vaccine Limited 10.18. Valneva SE 10.19. VBI Vaccines 10.20. PT Bio Farma

About This Report

Report ID 148585
Category Healthcare
Published Date May 2022
Updated Date
Contact Us